City snapshot: Haleon grows first quarter sales on price increases

Haleon Sensodyne

FTSE 100 consumer health player Haleon has posted a ‘solid’ start to the year, despite a volume and headline revenue decline in the first three months of 2024.

Already have an account? Sign in here

Want access to this article?

Register for LIMITED access

REGISTER FOR FREE

Get PREMIUM access for £1 a week

SUBSCRIBE NOW